# TB-500 reported effects and safety — What the research and community record show > What research-use communities report about TB-500 effects, benefits and adverse events — labeled anecdotal — alongside cited safety cautions from the published literature. Community-reported effects from TB-500 research-use accounts, clearly labeled as anecdotal, alongside cited safety and risk considerations drawn from the peer-reviewed record. ## The short version TB-500 is the synthetic Ac-LKKTETQ fragment of Thymosin Beta-4, studied mainly in cell and animal models where the full parent protein accelerates wound healing, supports cardiac and neural repair, and modulates inflammation [1][3][6][8][25]. No controlled human trial of TB-500 itself has been completed, so the human evidence base is thin. This page presents two things: first, what people in research-use communities actually report (clearly labeled as anecdotal, not clinical evidence); and second, the safety and risk considerations that emerge from the preclinical and regulatory record. For the detailed mechanism and published trial results, see the [research page](/research). ## What people report **All of the following are anecdotal, not clinical evidence.** These accounts come from research-use forums, athletic and biohacker community discussions, and research-supplier review pages — individual experiences, not results from placebo-controlled studies. **Very commonly reported benefits:** Faster recovery from tendon, ligament and muscle injuries — the main reason people in research-use communities reach for TB-500. Less joint pain, stiffness and better range of motion after a few weeks. **Frequently to occasionally reported benefits:** Improved overall flexibility and mobility; a vague sense of reduced inflammation or calmer post-workout soreness; faster healing of cuts and skin irritation. **Rarely reported benefits:** Hair regrowth or thicker hair over four to eight weeks — a minor and inconsistent signal. **Adverse effects:** Injection-site redness, swelling or aching is the most common complaint (very commonly reported) — typically mild and resolving within a day or two, consistent with injected peptides generally. Temporary tiredness or lethargy in the first few days is frequently reported, usually fading with continued use. Occasionally reported: brief head rush, lightheadedness or headache shortly after injecting; a mild flu-like feeling in the first one to two days. Rarely reported: nausea (more associated with larger amounts), a temporary heightened awareness of an existing injury in the first week or two, and short-lived mood changes. ## Safety and cautions The following cautions are drawn from the published preclinical and regulatory literature, not from personal reports. **Human safety data is essentially absent for TB-500 itself.** No completed controlled human trial of the seven-amino-acid heptapeptide exists. A 2026 sports-medicine review of unapproved peptides concluded that compounds like TB-500 show promise in animal models but carry scarce human safety data and operate largely outside regulatory oversight [27]. The Phase I safety data that do exist — reassuring as they are — belong to full-length recombinant Tβ4 at IV doses up to 1,260 mg, a different molecule [13]. **Theoretical cancer and tumor-growth concern.** This is the safety risk that appears most consistently in the peer-reviewed literature on Tβ4. The parent protein is overexpressed in several cancers and has been linked in preclinical models to tumor metastasis and angiogenesis [28][29]. The same pro-migration, pro-blood-vessel properties that may aid tissue repair could, in principle, support tumor progression. This concern has not been directly measured for TB-500 in humans, but anyone with a current or past cancer, or a strong family cancer risk, is the group most often flagged in discussion of this theoretical risk. **Banned in competitive sport.** TB-500 is prohibited by the World Anti-Doping Agency under both S2 (Peptide Hormones, Growth Factors) and S0 (Non-Approved Substances) of the WADA Prohibited List [30]. Anti-doping laboratories have developed LC-MS methods to detect TB-500 and its breakdown products in plasma and urine [30]. A positive test can end an athlete's eligibility regardless of any claimed recovery benefit. **Reported benefits may overstate what the peptide actually does.** An honest animal study found a key null result: in dystrophin-deficient mice given long-term thymosin beta-4, the number of regenerating muscle fibers increased, but there were no improvements in muscle strength, heart function or fibrosis levels [31]. More histological regeneration did not translate into better function — a caution against assuming felt improvements reflect real structural repair. **TB-500 is a fragment, not the full Thymosin Beta-4 protein.** The encouraging efficacy research was conducted almost entirely with the full 43-amino-acid parent protein. TB-500 preserves the actin-binding LKKTETQ motif but not most of the downstream signalling surface — PINCH-ILK-Akt, NF-κB binding, Meprin-α cleavage to Ac-SDKP, and Notch/VEGF/HIF-1α induction in endothelium — that the clinical and preclinical record actually measures [30][25]. Applying parent-protein results to the fragment is an extrapolation that has not been confirmed in head-to-head comparisons. **Research-grade product quality is not guaranteed.** TB-500 sold for research use is not manufactured to medicine-grade standards. Identity, purity and peptide sequence can vary between suppliers. Analytical characterization work on TB-500 preparations exists partly because doping-control laboratories needed to characterize them [32]. Unknown purity adds risk that is separate from, and on top of, the peptide's own pharmacology. **Theoretical cautions in pregnancy, breastfeeding, surgery and clotting.** Because Tβ4 influences basic processes like cell migration and blood-vessel formation — processes central to development and to platelet function — these populations are flagged as a precautionary matter in the absence of any human safety data. These are mechanism-based concerns, not documented findings in human studies of TB-500. --- An independent editorial console for the peer-reviewed record — not a clinic, not a vendor, not medical advice.